334 related articles for article (PubMed ID: 18341636)
1. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
2. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
3. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Br J Haematol; 2004 Nov; 127(3):285-91. PubMed ID: 15491287
[TBL] [Abstract][Full Text] [Related]
4. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
6. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
7. The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
Lucena-Araujo AR; Panepucci RA; dos Santos GA; Jácomo RH; Santana-Lemos BA; Lima AS; Garcia AB; Araújo AG; Falcão RP; Rego EM
Br J Haematol; 2008 Jul; 142(1):74-8. PubMed ID: 18422993
[TBL] [Abstract][Full Text] [Related]
8. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
9. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Br J Haematol; 2006 Jan; 132(2):230-6. PubMed ID: 16398657
[TBL] [Abstract][Full Text] [Related]
10. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
[TBL] [Abstract][Full Text] [Related]
11. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
12. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Pettitt AR
Br J Haematol; 2004 Nov; 127(4):425-8. PubMed ID: 15521919
[TBL] [Abstract][Full Text] [Related]
13. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
14. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
15. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
16. The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.
Best OG; Singh N; Forsyth C; Mulligan SP
Br J Haematol; 2010 Oct; 151(2):185-8. PubMed ID: 20738310
[TBL] [Abstract][Full Text] [Related]
17. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
18. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
[TBL] [Abstract][Full Text] [Related]
19. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
